- Home
- LPTX vs GNTA Comparison
LPTX vs GNTA Comparison
Compare LPTX & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- GNTA
- Stock Information
- Founded
- LPTX 2011
- GNTA 2014
- Country
- LPTX United States
- GNTA Italy
- Employees
- LPTX N/A
- GNTA N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LPTX Health Care
- GNTA Health Care
- Exchange
- LPTX Nasdaq
- GNTA Nasdaq
- Market Cap
- LPTX 99.5M
- GNTA 96.0M
- IPO Year
- LPTX N/A
- GNTA 2021
- Fundamental
- Price
- LPTX $3.11
- GNTA $5.23
- Analyst Decision
- LPTX Strong Buy
- GNTA Strong Buy
- Analyst Count
- LPTX 3
- GNTA 1
- Target Price
- LPTX $7.50
- GNTA $25.00
- AVG Volume (30 Days)
- LPTX 437.3K
- GNTA 5.1K
- Earning Date
- LPTX 11-13-2024
- GNTA 01-01-0001
- Dividend Yield
- LPTX N/A
- GNTA N/A
- EPS Growth
- LPTX N/A
- GNTA N/A
- EPS
- LPTX N/A
- GNTA N/A
- Revenue
- LPTX N/A
- GNTA N/A
- Revenue This Year
- LPTX N/A
- GNTA N/A
- Revenue Next Year
- LPTX N/A
- GNTA N/A
- P/E Ratio
- LPTX N/A
- GNTA N/A
- Revenue Growth
- LPTX N/A
- GNTA N/A
- 52 Week Low
- LPTX $1.68
- GNTA $2.20
- 52 Week High
- LPTX $5.00
- GNTA $7.28
- Technical
- Relative Strength Index (RSI)
- LPTX 51.79
- GNTA 50.15
- Support Level
- LPTX $2.87
- GNTA $5.13
- Resistance Level
- LPTX $3.12
- GNTA $5.27
- Average True Range (ATR)
- LPTX 0.28
- GNTA 0.30
- MACD
- LPTX 0.02
- GNTA 0.00
- Stochastic Oscillator
- LPTX 49.42
- GNTA 40.26
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.